Introducing OmniSeq INSIGHTSM
OmniSeq INSIGHTSM is a comprehensive, tissue-based, next generation sequencing genomic profiling device clinically and analytically validated for all solid tumors. The test is designed to detect genomic variants, signatures, and immune gene expression to provide physicians with clinically actionable evidence to inform therapeutic treatment decisions and identify potential clinical trial options based on an individual genomic profile of each patient. Results are intended for use by qualified health care professionals in accordance with professional guidelines in oncology for management of patients with solid neoplasms, and is not conclusive or prescriptive for labeled use of any specific therapeutic product.
All Solid Tumors
Preferred: FFPE Block
Alternate: 20 unstained slides
Typical Turnaround Time
10 days or less from receipt of specimen
Expanded Insight = Increased Options
Marker-Driven FDA Approved Therapy Associations
Markers with NCCN Therapeutic Guidance Evidence
Markers with Clinical Trial Associations
Industry-guided content for a comprehensive view of cancer-related fusion genes, detecting common and novel fusions.
Detect Fusions Missed By DNA-seq
Effectively Match Patients to the Right Trial
MOLECULAR + IMMUNE PROFILING = MORE PATIENT OPTIONS
PROFILING THE ACTIONABLE CANCER GENOME
Comprehensive Trial Matching Across the Actionable Cancer Genome for Solid Tumors
Expertly Curated Clinical Trial Matching Assessing Biomarker-Based Eligibility Criteria, Multi-Arm Study Designs and Treatment Context Assertions
PROFILING THE TUMOR MICROENVIRONMENT
Increase Clinical Trial Options by Targeting Biomarkers Involved in the Adaptive Immune System
Understanding the Anti-Cancer Immune Response is Critical to Adapt Therapies to the Cancer Phenotype.
OmniSeq Delivers the Only Test Matching Trials to Tumor-Immune Mechanisms and Low-Expressing Genes Involved in Inflammatory Signaling
Trust a test provider ISO13485 CERTIFIED to design, develop and deliver DNA and RNA testing for the medical management and identification of genomic and immune biomarkers in oncology.